Lund, Sweden - June 30, 2020 - BioInvent International AB (publ) (OMXS: BINV) today announced that the company's total number of shares as per June 30, 2020 amounts to 583,697,428 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of MSEK 113 to Swedish and international institutional investors, including Swedbank Robur Medica and Handelsbanken Healthcare Fund, by issuance of 81,927,532 shares, announced on June 9, 2020.
BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Two preclinical programs in solid tumors are expected to enter clinical trials by the end of 2020. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Martin Welschof, CEO Hans Herklots, LifeSci Advisors
+46 (0)46 286 85 50 +41 79 598 71 49
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
This information is information that BioInvent International AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 10.45 a.m. CET on June 30, 2020.